BYSI News and Press, BeyondSpring Inc. From 08/04/21

Shares of BeyondSpring (NASDAQ: BYSI) soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. By the close of trading, BeyondSpring's stock price was up 176% after rising as much as 211% earlie...

Wednesday was generally a down day in the stock market, with major indexes showing losses of as much as 1%. However, the Nasdaq Composite (NASDAQINDEX: ^IXIC) held up quite well, just barely falling below the unchanged mark as of noon EDT. Most people think of tech stocks when t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of BeyondSpring (NASDAQ: BYSI ) stock are taking off on Wednesday following an important update regarding the firm’s lung cancer treatment. Source: CI Photos / Shutterstock.com The pharmaceutical c...

BeyondSpring (BYSI +158.2%) has more than doubled in value to reach a two-year high in morning hours after the company said its DUBLIN-3 trial met the primary endpoint for Plinabulin and docetaxel (DP) combination in non-small cell lung cancer. Seeing “a dramatic shift in the thes...

Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...

BeyondSpring (NASDAQ:BYSI) soars 332.5% premarket after announcing positive topline data of DUBLIN-3 trial in plinabulin in combination with docetaxel (DP) to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (D) (n=559). The combination met the pri...

Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel. Study met key secondary endpoints showing statistically significant improvement for the combination against docetaxel alone in ORR, PFS, and 24-...

BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other. Below is an overview of plinabulin and a comparison. For further details see: BeyondSpring's Plinabulin: Upcom...

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Direct...

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech Focus ...